---
document_datetime: 2023-09-21 17:03:18
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/duotrav-epar-procedural-steps-taken-authorisation_en.pdf
document_name: duotrav-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5083647
conversion_datetime: 2025-12-27 23:02:21.080921
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Alcon  Laboratories  (U.K.)  Ltd.  submitted  on  22  April  2005  an  application  for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  DuoTrav,  through  the centralised procedure.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP.

## Licensing status:

The product was not licensed in any country at the time of submission of the application. A new application was filed in the following countries: USA (13/11/03), Australia (08/06/04), New Zealand (14/07/04).

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: G. Calvo Rojas

Co-Rapporteur: K. Broich

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 22 April 2005.
- The procedure started on 18 May 2005.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 5 August 2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 29 July 2005.
- During the meeting on 13-15 September 2005, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 16 September 2005.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  16 November 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 3 January 2006.
- During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP list of outstanding issues on 30 January 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CHMP members on 8 February 2006.
- During  the  meeting  on  20-23  February  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for

<div style=\"page-break-after: always\"></div>

granting a Marketing Authorisation to DuoTrav on 23 February 2006. The applicant provided the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  22 February 2006.

- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 24 April 2006.